In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
When compared to reconstructive bone surgery (guided bone regeneration), in a partially edentulous site, periodontal regeneration site has some disadvantages in terms of primary wound healing [33]
Research suggests it has a relatively mild safety profile, but long-term safety studies are still limited
Clinical trial data from the SURMOUNT-1 study showed that gastrointestinal adverse events were significantly more common during dose escalation periods (Jastreboff et al., 2022, NEJM)
Muscle Satellite Cells: Unlike many weight-loss agents (such as GLP-1 agonists) which can cause muscle atrophy, 5-Amino-1MQ is researched for its potential to enhance muscle function